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Because epigenetic alterations are believed to be involved in the repression of tumor suppressor genes and the promotion of
tumorigenesis in cancers, novel compounds endowed with histone deacetylase (HDAC) inhibitory activity are an attractive
therapeutic approach. Indeed, the potential of HDAC inhibitors for cancer therapy has been explored in preclinical models, and
some agents approved for hematologic malignancies have reached the clinical setting. HDAC inhibitors are able to mediate the
induction of both apoptosis and autophagy, which are related to anticancer activity in a variety of cancer cell lines. Given the
inherent resistance to apoptosis that characterizes cancer, the targeting of alternative pathways is an attractive strategy to improve
anti-tumor therapy. The activation of autophagy represents novel cancer treatment targets. This paper aims to critically discuss
how the anticancer potential of HDAC inhibitors may elicit a response to human cancers through diﬀerent cell pathways leading
to cell death.
1.Introduction
An ideal anticancer agent should be toxic to malignant
cells with minimum toxicity towards normal cells. Currently,
there are only a limited number of such agents available for
clinical use; thus, the development of novel cancer-selective
drugs is an important and challenging task. Caspase-
mediated apoptosis, involving both intrinsic and extrinsic
pathways, is the main mechanism of action of most current
anticancer treatments. Several anticancer drugs have been
shown to induce autophagy as well as apoptosis. Autophagy
is a catabolic pathway whereby cytoplasmic proteins and
organelles are sequestered in vacuoles and delivered to
lysosomes for degradation and recycling; however, the role
of autophagy in cancer development and in the response to
therapy is still controversial, requiring further investigation.
Chemoresistance may be due to epigenetic alterations
leading to defects in the apoptotic pathway; therefore,
modulating epigenetic changes may increase the eﬃcacy
of chemotherapy. It is possible to interfere with epigenetic
modiﬁcations, such as histone acetylation, using relatively
speciﬁc and reversible inhibitors. In addition, the induc-
tion of autophagy has been also observed in malignant
cells following treatment with histone deacetylase (HDAC)
inhibitors [1]. HDAC inhibitors are promising new agents
for the treatment of multiple myeloma as they promote
hyperacetylation and activate chromatin remodeling. HDAC
inhibition leads to many changes at the molecular and cel-
lular levels. HDAC inhibitors preferentially kill transformed
cells or cancer cells in both cell cultures and animal models.
Although further investigation is required to fully elucidate
theconsequencesofbothautophagyandapoptosisinduction
by treatment with HDAC inhibitors, the pharmacological
inhibition of HDAC provides a new therapeutic basis for
targeting cell death processes.
2.HDAC Family
In addition to DNA mutations (genetic changes), most
cells in multicellular organisms result from aberrations
in chromatin-modifying proteins, such as HDAC and
DNA methyltransferase (epigenetic changes). It became2 Journal of Biomedicine and Biotechnology
increasingly evident that cancer formation and persistence
may be caused not only by genetic mutations but also by
changes in the patterns of epigenetic modiﬁcations [2].
Epigenetic modiﬁcations are of profound importance to
cells and appear to play roles in many, if not all, biological
processes throughout life. In particular, acetylation and
deacetylation of the lysine residues on histone proteins
play a key role in the regulation of gene transcription [3].
Whereas histone acetyltransferase catalyzes the acetylation of
histones and relaxes chromatin to increase the accessibility
of transcription factors to the promoters of the target genes,
HDACs remove the acetyl groups from histones and repress
transcription [4]. In the discovery of drugs, HDAC has
become a novel target for the treatment of cancer and other
diseases. Inhibition of HDAC activity leads to the acetylation
of histones and nonhistone proteins, and alterations in target
gene expression are related to changes induced by HDAC
inhibition.
Accordingto phylogenetic analyses and sequencehomol-
ogy,theHDACfamily consistsofatleast 18members divided
into two families and four classes in eukaryotic cells. These
two families are the classical and sirtuin families. HDACs
are categorized into class I (HDACs 1, 2, 3, and 8), class IIa
(HDACs 4, 5, 7, and 9), class IIb (HDACs 6 and 10), class III
(SIRTs), and class IV (HDAC11) [5]. Class I and II have zinc
as a cofactor, so they are hydrolases which contain zinc. Class
III, which is a series of NAD-dependent Sir2 families, diﬀers
from other HDAC classes. Class I and II HDACs are mainly
found to be involved in cancer pathogenesis. Class I are
found exclusively in the nucleus, whereas in certain cellular
signals, class II shuttle between the nucleus and cytoplasm.
While human HDACsare well characterized in terms oftheir
catalytic domains, the discovery of type-speciﬁc inhibitors is
important for anticancer therapies.
3.HDAC Inhibitors
HDAC inhibitors are emerging as potent anticancer agents
that can reactivate gene expression and restore the capability
ofmalignantcellstoundergoprogrammedcelldeath.Several
natural and synthetic compounds are currently known to
inhibit HDACs (Table 1). Since HDAC inhibitors do not
inhibit all HDAC isoforms to the same extent, these agents
can be grouped into pan- and class I-speciﬁc inhibitors
[5]. Hydroxamic acids (TSA, SAHA, LAQ824, and CBHA)
and pyroxamic acids (PXD101 and CRA-026440) are pan-
HDAC inhibitors targeting class I, II, and IV HDACs in the
nanomolar range [17]. Incontrast, carboxylic acids(valproic
acid and sodium butyrate) and benzamides (MS275, CI-
994, and MGCD0103) or cyclic tetrapeptides (trapoxin,
depsipeptide and spiruchostatin A) are rather class I-speciﬁc
HDAC inhibitors [18].
HDACs are often overexpressed in various types of
cancers, compared with the corresponding normal tissues,
and their overexpression is correlated with a poor prognosis
[19]. Currently, at least 15 diﬀerent HDAC inhibitors
are being used in clinical trials as a part of mono- or
combination therapies. For example, the orally available
pan-inhibitor LBH589 (panobinostat) is currently being
developed for several hematological malignancies. SAHA
(vorinostat) has been approved for marketing based on data
from a large Phase II trial of patients with cutaneous T-
cell lymphoma that demonstrated a 30% objective response
rate [6]. The class I-selective intravenously delivered agent
FK228 (romidepsin), has also shown promising eﬃcacy
in patients with cutaneous T-cell lymphoma, with an
overall objective response rate of 32%. The class I-selective
orally available compound, MGCD0103 (mocetinostat), is
in development for multiple solid and hematologic cancers
[13]. Clinical trials of several HDAC inhibitors include
patients with a wide variety of hematologic and solid neo-
plasms, including chronic lymphatic leukemia, Hodgkin’s
lymphoma, myeloproliferative disorder, B-cell lymphoma,
acute myeloid leukemia, multiple myeloma, head and neck
cancer, brain tumors, melanoma, lung cancer, hepatocellular
cancer, breast cancer, ovarian cancer, renal cell carcinoma,
and pancreatic adenocarcinoma. However, the main side
eﬀects of HDAC inhibitor, SAHA, are fatigue, nausea,
anorexia, diarrhea, thrombus formation, thrombocytopenia,
neutropenia, anemia, myalgia, hypokalemia and hypophos-
phatemia. Reversible thrombocytopenia has been seen with
almost all HDAC inhibitors in the clinic and appears to
be a mechanism-related class eﬀect. By targeting only the
most relevant HDAC isoform, it may be possible to greatly
improve the eﬃcacy by removing certain toxicities that may
be associated with the inhibition of multiple isoforms.
4.Programmed Cell Death(PCD)
Cell death is a result of an unsuccessful cytoprotective mech-
anism against intracellular and extracellular stressors, and it
is broadly divided into three forms: apoptosis, autophagy,
and necrosis (Table 2). Morphologically, type I cell death
(apoptosis) is characterized by chromatin condensation and
DNA fragmentation. Biochemically, apoptosis is charac-
terized by double-stranded cleavage at the linker regions
between nucleosomes, resulting in the formation of multi-
ple DNA fragments, and phosphatidylserine externalization
accompanied by a series of gene and protein expressions.
In the extrinsic pathway, apoptosis is mediated by death
receptors on the cell surface, while in the intrinsic pathway,
mitochondria play an important role. In both pathways,
activated caspases (cysteine aspartic acid-speciﬁc proteases)
cleavetheirsubstratesandactivateotherdownstreamcellular
substrates. Type II cell death (autophagy) is characterized
by the massive accumulation of double-membrane vesi-
cles, commonly referred to as autophagosomes. In general,
autophagy promotes the survival of stress; however, there is
increasing evidence that when autophagy is overstimulated,
it can progress to autophagic cell death. It has been also
documented that malignant cell types undergo autophagic
cell death when responding to anticancer agents, indicating
the potential utility of autophagic cell death induction in
cancer therapy. Type III cell death (necrosis) is characterized
by oncosis and plasma membrane rupture [20]. Necrosis
is an uncontrolled cell death manifesting osmotic disper-
sion of cells and organelles. While apoptosis involves the
rapid destruction of all cellular structures and organelles,Journal of Biomedicine and Biotechnology 3
Table 1: Characteristics of HDAC inhibitors in clinical trials.
Chemistry Compounds HDAC Targets Clinical trials Ref
Hydroxymates
SAHA (vorinostat) Classes I, II, and IV Phase III∗ [6]
PXD101 (belinostat) Classes I, and IIa, HDAC6 Phase II [7]
Trichostatin A Classes I and II Toxic [8]
LAQ824(dacinostat) Classes I and II Phase I [9]
PCI24781 Classes I and IIb Phase I [10]
LBH589 (panobinostat) Classes I and IIa Phase II [11]
Cyclic tetrapeptides FK228 (romidepsin) HDAC1, 2, 4, 6 Phase II [12]
Benzamides MGCD0103 (mocetinostat) HDAC1, 2, 3, 11 Phase II [13]
MS275 (entinostat) HDAC1, 2, 3, 9 Phase II [14]
Short-chain fatty acids Valproic acid Classes I and IIa Phase II [15]
Butyrate Classes I and IIa Phase II [16]
∗Approved (cutaneous T-cell lymphoma).
autophagy is a slow, spatially restricted phenomenon in
which parts of the cytoplasm are sequestered within double-
membraned vacuoles and ﬁnally digested by lysosomal
hydrolases [21].
5. ApoptosisInducedby HDAC Inhibitors
All HDAC inhibitors have been reported to activate either
an extrinsic or intrinsic pathway or both of these cell death
pathways in many cancer models [22]. The death-receptor
pathway is activated when ligands, such as Fas or TRAIL,
bind to their death receptors. It was observed that MS275
(entinostat) as well as SAHA induced TRAIL expression
without altering DR4 or DR5 levels in breast cancer cells,
which was mediated via SP1 and markedly enhanced
adriamycin cytotoxicity in these cells [23]. This resulted
in the recruitment of an adaptor protein, FADD, and the
activation of caspase-8. The mitochondrial pathway is
activated by stress stimuli (chemotherapeutic agents) that
disrupt the mitochondrial membrane, causing the release of
proteins, including cytochrome c and SMAC. Cytochrome
c release leads to apoptosome formation and activation of
caspase-9. Caspase-8 and caspase-9 can then cleavecaspases-
3, -6, and -7, culminating in apoptosis. SAHA and MS275
induced mitochondrial dysfunction and apoptosis through
enhanced ROS generation, XIAP downregulation and JNK1
activation [24]. Various pro- (Bax, Bak, Bim, Bid, etc.) and
antiapoptotic (Bcl-2, Bcl-xL, Mcl-1, etc.) proteins regulate
these cell death pathways. HDAC inhibitors, including TSA,
FK228, SAHA, and LBH589, decrease the expression of
Bcl-2, Bcl-xL and XIAP, and enhance the expression of pro-
apoptotic proteins, such as Bax and Bak, thereby enhancing
TRAIL-mediated cytotoxicity in a variety of cancer cells via
the ampliﬁcation of intrinsic as well as extrinsic apoptotic
pathways [25]. Using siRNA approaches targeting Bim,
the contribution of Bim to TSA-induced mitochondrial
apoptosis was conﬁrmed [26]. In addition, serine protease-
dependent and caspase-independent apoptosis is induced by
treatment with the pan-HDAC inhibitor, TSA, in pancreatic
ductaladenocarcinomacelllines[27].Thisprocesscorrelates
with the initially increased expression of the multidomain
proapoptotic Bcl-2 family member, Bax, and the subsequent
release of AIF and Omi/Htr-A2 from mitochondria. The Bax
tumor suppressor gene is downregulated by SIRT1 through
the DNA end-binding factor, Ku70. In the absence of SIRT1,
Ku70 might be hyper-acetylated, leading to the disruption of
Ku70-Bax interaction. This in turn releases more Bax, which
promotes apoptosis [28]. HDAC2 inhibition opens the
locus of the epigenetically silenced NOXA gene, a BH3-only
protein and apical initiator of apoptosis [29]. Given the
multitude of cellular eﬀects triggered by HDAC inhibitors, it
is probable that several diﬀerent mechanisms contribute to
their anticancer activity. Another mechanism of cancer cell
death resulting from HDAC inhibitor treatment is discussed
below.
6. Autophagy Induced by HDAC Inhibitors
While autophagy has become one of the most attractive
topics in cancer research, the current autophagy studies are
often viewed as confusing, because of its association with
apparently contradictory roles, such as survival and cell
death, depending on the model used [30]. A number of
anticancer therapies, including HDAC inhibitors, have been
observed to induce autophagy in human cancer cell lines.
6.1. Prosurvival Functions. Autophagy is an evolutionarily
conserved cell survival pathway that enables cells to recoup
ATP and other critical biosynthetic molecules during nutri-
ent deprivation or exposure to hypoxia, which are hall-
marks of the tumor microenvironment. The disruption of
autophagy with the antimalarial drug, chloroquine, strongly
enhanced SAHA-mediated apoptosis in colon cancer cells,
knockdown of the essential Atg7 also sensitized cells to
SAHA-induced apoptosis [31]. HDAC6, a class II HDAC
isotype, is directly involved in the autophagic degradation
of the cell; therefore, drugs that impair autophagy could
theoretically potentiate the anticancer eﬃcacy of SAHA and
other HDAC inhibitors by disabling this important cell
survival mechanism.4 Journal of Biomedicine and Biotechnology
6.2. Prodeath Functions. The cytotoxic eﬀects of autophagy
may be explained by the extensive autophagicdegradation of
intracellular content or by the interfacing of the autophagic
process to proapoptotic signals. Persistent autophagy in
response to cellular stress states serves as a potent death
signal, as in the case of therapy-induced autophagy,a speciﬁc
nonapoptotic death pathway triggered upon exposure to
chemotherapeutic compounds. In general, autophagic cell
death is caspase independent and does not involve clas-
sic DNA laddering; however, the mechanisms underlying
autophagic cell death are mostly undeﬁned. A link between
autophagy and related autophagic cell death has been
demonstratedusingpharmacological(3-methyladenine)and
genetic (silencing of Atg5, Atg7, and Beclin-1) approaches for
the suppression of autophagy. In chondrosarcoma cell lines,
SAHA induced autophagy-associated cell death, as shown
by the detection of autophagosome-speciﬁc protein and
speciﬁc ultrastructural morphology in the cytoplasm [32].
In HeLa cells, HDAC inhibitors (butyrate and SAHA) can
induce both mitochondria-mediated apoptosis and caspase-
independent autophagic cell death. HeLa cells with APAF-1
knockout or Bcl-xL overexpression were induced to undergo
autophagic cell death when cultured with SAHA or butyrate
[1]. Therefore, it is reasonable to propose that the induction
ofautophagiccelldeathmay beusedasatherapeuticstrategy
to treat cancer.
7.MolecularMechanisms of
HDAC-Induced Autophagy
Many signaling pathways, including mTOR, AIF, ROS,
CDKs, and HDAC1/6, play important roles in regulating
HDAC-inducedautophagy(Table 3). Their molecularmech-
anisms and regulation of autophagy are discussed below.
7.1. mTOR. mTOR playsa role in the initiation and matura-
tionofautophagybycontrollingsignaltransductioncascades
involved in this process, acts as a good gatekeeper in
autophagy,andexerts aninhibitory eﬀectonautophagy[40].
Both mTOR and phospho-mTOR expressions were strongly
decreased in SAHA-treated endometrial stromal sarcoma
(ESS-1) cells in a concentration-dependent manner [33]. It
seems that SAHA modulates the stability and/or the degra-
dation mechanisms ofmTOR at the protein level.SAHAalso
exerted an inﬂuence on mTOR phosphorylation. The level
of phospho-S6rp, which plays a regulatory role in the mTOR
pathway, was also aﬀected by SAHA. S6rp phosphorylation
is directly involved in the control of autophagic processes.
The same results were found in ESS-1 treated by rapamycin,
a well-known mTOR inhibitor. Further investigations are
needed to elucidate the exact pharmacological mechanisms
of diﬀerent HDAC inhibitors in diﬀerent experimental
systems and to clarify whether HDAC inhibitors modulate
the expression and phosphorylation of mTOR directly or act
somewhere upstream of mTOR.
7.2. AIF. It was examined in malignant rhabdoid tumor cells
whether HDAC-inhibitor- (FK228-) mediated autophagy
involved AIF, which acts as a safeguard executioner in
cancer cells with faulty caspase activation [34]. FK228
treatment induced the redistribution of AIF to the nucleus,
in either the presence or absence of zVAD-fmk. siRNA
against AIF prevented the redistribution of LC3 into punc-
tate cytoplasmic structures and blocked FK228-induced
autophagy. AIF siRNA also decreased the conversion of LC3-
I to LC3-II, as analyzed by Western blotting. Treatment
withautophagyinhibitors(chloroquineor3-methyladenine)
increased FK228-induced cell death. These ﬁndings suggest
thatAIFcontributestotheautophagyinducedbyFK228,and
disrupting autophagy enhances FK228-induced apoptosis.
7.3. ROS. Targeting the autophagy pathway might enhance
the anticancer activity of SAHA, and autophagy inhibitors
would synergistically potentiate the proapoptotic eﬀects of
SAHA. SAHA has pleiotropic eﬀects that contribute to
its mechanism of action in malignant cells, including the
generation of ROS, and this has been shown to be a
critical eventin SAHA-inducedcell death [41]. To determine
whether chloroquine may modulate SAHA-induced ROS
generation, the intracellular levels of the oxygen radical
superoxide (O2
−) were quantiﬁed after 12h treatment with
chloroquine, SAHA, and the combination of chloroquine
and SAHA in K562 and LAMA 84 cells [35]. In both cell
lines, there were marked increases in the generation of O2
−
in cellstreated witha combinationofchloroquineand SAHA
compared with cells treated with either single agent. Cells
pretreated with N-acetyl-cysteine displayed signiﬁcantly
reduced apoptosis induction in response to chloroquine and
SAHA. It is possible that the initial ROS release triggered
autophagy as a protective defense mechanism of cancer cells
to deal with SAHA, but the temporal order of protective
autophagy is followed by apoptosis, as if autophagy sets the
stage for apoptosis to kill prostate cancer cells after a futile
attempt to rescue them from death.
7.4. p21CIP/WAF1. Both a novel sulfur-containing hydroxam-
ate HDAC inhibitor, H40, and SAHA induced autophagy
in prostate cancer PC-3M cells in a concentration-
dependent manner, which correlated well with their cyto-
toxic eﬀects. These HDAC inhibitors signiﬁcantly increased
CDK inhibitor p21CIP/WAF1 mRNA and protein expression
in both PC-3M and HL-60 cells in concentrations within
their cytotoxic ranges [36]. The upregulation of p21CIP/WAF1
correlatedwith reducedsensitivity andblockedtheapoptotic
mechanism, and these cells seemed to die by autophagy.
Recently, silencing of HDAC3 has been found to induce
the expression of p21CIP/WAF1 and cell cycle arrest in the
G2/M phase in colon cancer cells [42]. HDAC4 was shown
to suppress p21CIP/WAF1 in ovarian carcinoma cells, cervical
cancer cells, glioblastoma cells and breast cancer cells in a
nonredundant fashion [43]. These results suggest that the
presence of p21CIP/WAF1 determines which type of PCD the
cell undergoes.
7.5. HDAC1 and HDAC6. HDAC inhibition leads to many
changes at the molecular and cellular levels. Class I HDACJournal of Biomedicine and Biotechnology 5
Table 2: Characteristic features of programmed cell death.
Programmed cell death (PCD) Feature Key regulators Measurements
Apoptosis (type I PCD)
Chromatincondensation Caspases Caspase activation
DNA laddering Cytochrome c DNA fragmentation
Blebbing (nuclear, cytoplasmic)
Apoptotic bodies Bcl-2 family members Annexin V
Autophagy (type II PCD)
Blebbing
Autophagy. genes: beclin, LC3, Atg1,
Atg5,a n dAtg7
LC3 localization
Autophagic vesicles
Degradation of Golgi Autophagic vesicles
No DNA laddering
Necrosis (type III PCD)
Swollen organelles
RIPK1, TRAF2, PARP, and Calpains
Extracellular HMGB1
Random DNA degradation
Cytoplasmic membrane rupture S100 family members
Potent inﬂammatory response
Table 3: Eﬀects of HDAC inhibitor on the process of autophagy.
Mechanisms HDAC inhibitors Cell lines∗ Detection methods Ref
mTOR SAHA ESS-1 Phosphorylation (mTOR) [33]
AIF FK228 MRT siRNA (AIF) [34]
ROS SAHA K562, LAMA84 N-acetyl-cysteine, chloroquine [35]
p21CIP/WAF1 H40, SAHA PC-3M, HL-60 mRNA, protein expression [36]
HDAC1 FK228 HeLa siRNA (HDAC1) [37]
HDAC6 Tubacin MEF siRNA (HDAC6) [38]
Mitochondria LBH589, LAQ824 Eμ-myc lymphoma Knockout (Apaf-1, caspase-9) [39]
∗ESS-1: endometrial stromal sarcoma cells; LAMA84: human chronic myeloid leukemia; MEF: mouse embryonic ﬁbroblasts; MRT: malignant rhabdoid
tumors.
inhibitor, FK228, led to autophagic activities through the
formation of autophagic vacuoles and the increase of acidic
compartments inHeLacells. WhenHDAC1siRNAwasused,
the amount of HDAC1 mRNA was signiﬁcantly decreased
in knocked-down cells, and HDAC1 inhibition induced the
conversion of LC3-I to LC3-II which leads to autophagy in
HeLa cells [37]. Thus, HDAC1 may play a role in autophagy
because the inhibition of HDAC1 with a speciﬁc inhibitor or
siRNA can induce autophagy.
HDAC6 is a member of the class II HDAC family
and is known to deacetylate α-tubulin and increase cell
motility. The ubiquitin-binding deacetylase, HDAC6, was
also identiﬁed as a central component of basal autophagy
that targets protein aggregates and damages mitochondria;
however, HDAC6 is not required for autophagy activation;
rather,itcontrolsthefusionofautophagosomestolysosomes
[38]. HDAC6 promotes these fusion events by recruiting a
cortactin-dependent, actin-remodelling machinery to ubiq-
uitinated protein aggregates, where the assembly of F-actin
facilitates autophagosome-lysosome fusion and clearance
of autophagic substrates. In addition, the observation that
tubacin, a selective inhibitor of HDAC6 deacetylase activity,
blocks LC3 recruitment suggests that deacetylation is essen-
tial for this process.
7.6. Mitochondrial Function. HDAC inhibitors, LAQ824
(dacinostat) and LBH589, induce the apoptosis of Eμ-myc
lymphomas via the intrinsic apoptotic pathway. Cells that
inhibited the later stages of apoptosis signaling, through
the knockout of apaf-1 or caspase-9, displayed morphologic
features of autophagy but did not diminish the eﬀects of
LAQ824 and LBH589 on mitochondrial membrane perme-
abilization [39].
8.Relationshipbetween
AutophagyandApoptosis
Recently,severalanticancerdrugshavebeenshowntoinduce
not only apoptosis, but also autophagy in cancer cells
[44]. The relationship between autophagy and apoptosis is
complex and varies with cell types and the speciﬁc stress
placed upon the cell [45]. While the molecular mechanisms
leading to apoptosis have been elucidated to some extent
during the past 15 years, autophagic cell death is not well
characterized at the molecular level yet [46]. The induction
ofautophagiccelldeathmay beanidealapproach for cancers
that are resistant to apoptosis by anticancer therapies.
It is clear whether autophagy and apoptosis are strictly
interconnected, as highlighted by the ﬁnding that the two6 Journal of Biomedicine and Biotechnology
pathways share key molecular regulators. These are summa-
rized as follows.
(1) Caspase-3 inhibitor zDEVD-fmk upregulated auto-
phagy in the mouse lung cancer cells [47].
(2) Following genotoxic stress or oncogene activation,
the p53 tumor-suppressor protein is stabilized and
activated as a transcription factor, capable of induc-
ing apoptosis. Nuclear localization of p53 induces
autophagy, whereas cytoplasmic accumulation in-
hibits autophagy [48].
(3) Serum- and amino acid-starved LAMP2-negative
cells exhibited an accumulation of autophagic vac-
uoles and then succumbed to cell death with hall-
marks of apoptosis, such as loss of mitochondrial
transmembrane potential, caspase activation, and
chromatin condensation. Together, the accumulation
of autophagic vacuoles can precede apoptotic cell
death [49].
(4) Beclin-1 may be a critical molecular switch that
playsan important role in ﬁne-tuning autophagyand
apoptosis through caspase-9 [50].
(5) JNK and p53 may constitute an amplifying loop of
autophagic and apoptotic responses. JNK activation
results in phosphorylation of Bcl-2, which enhances
autophagyby disrupting theinteraction between Bcl-
2a n dB e c l i n - 1[ 51].
(6) The enforced expression of Atg5 not only promotes
autophagy but also enhances susceptibility toward
apoptotic stimuli irrespective of the cell type, indi-
cating that Atg5 is a molecular switch factor between
autophagy and apoptosis [52].
(7) Full-length Atg5 is an inducer of autophagy, whereas
an Atg5 fragment due to cleavage by calpain is pro-
apoptotic [53].
(8) The formation of autophagosomes occurred early
in the sequence of dexamethasone-induced events,
before Bak activation, loss of mitochondrial mem-
brane potential, and nuclear fragmentation, showing
that dexamethasone-induced autophagy not only lies
upstream of apoptosis but is also required for the
latter to occur [54].
(9) A novel Bcl-xL inhibitor, Z36, eﬃciently induces
autophagic cell death in HeLa cells through blocking
the interaction between Bcl-xL/Bcl-2 and Beclin-
1[ 55]. The antiapoptotic protein Bcl-2 is also an
antiautophagic protein through its interaction with
Beclin-1 [56].
(10) The stress induced by N-(4-hydroxyphenyl) retina-
mide triggers autophagy at a lower dose and apopto-
sis at a higher dose in glioma cells. At that time, ERK
wasspeciﬁcally activated ata lowerconcentrationbut
not at a higher concentration of retinamide [57].
(11) The kinetics of Ca2+ inﬂux correlated well with the
onset of apoptosis and autophagy, suggesting that
Ca2+ might play a direct role in these processes [58].
BAPTA abolished calcium inﬂux and signiﬁcantly
reduced autophagy and apoptosis.
(12) Employing 3-methyladenine, a PI3K inhibitor and
speciﬁc inhibitor of the autophagy pathway, en-
hanced the apoptotic level [59].
These ﬁndings argue against a deﬁnitive distinction
between type I (apoptotic) and type II (autophagic) cell
death.Thetwopathwaysarelinkedinasee-saw manner, such
that when apoptosis is inhibited, autophagy is initiated as a
backup mechanism and vice versa [60, 61].
9.Conclusions
HDAC enzymes aﬀect the acetylation status of histones
and other important cellular proteins, which have been
recognized as potentially useful therapeutic targets for a
broad range of human disorders. In particular, HDAC
inhibitors have emerged as major pharmacologic agents
f o rc a n c e rt h e r a p y .M o s tl i k e l y ,t h e s ea g e n t sw i l lb eu s e d
in combination with standard treatment regimens. Eﬀorts
to further develop these agents should focus on the thor-
ough evaluation of HDAC expression in diﬀerent human
cancers, the comprehensive analysis of the mechanisms of
action of various classes of HDAC inhibitors in vitro,a n d
the conﬁrmation of recently identiﬁed prognosticators of
response inclinicalsettings.However,most HDACinhibitors
target either all or at least a wide range of HDACs. This
creates the problem of the unspeciﬁc inhibition of several
HDACs, while the targeted blockade of speciﬁc single
HDACs might be more desirable. Class-speciﬁc side eﬀects
of pan-HDAC inhibitors have been reported, supporting
the requirement of selective inhibitor development. The
synthesis of HDAC inhibitors that selectively target HDACs
relevant to cancer initiation/progression may enhance the
antitumor eﬀects while decreasing the systemic toxicities of
HDAC inhibition in cancer patients. It can be expected that
the tissue- and time-speciﬁc disruption of single HDACs
will uncover even more the physiological functions of
particular HDACs.Althoughinitial results examining HDAC
inhibitors, administered eitheraloneorincombination,have
beendisappointing,attentionhasnowturnedtomorepotent
andselectivecompoundsthatmayprovetobemoreeﬀective.
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